ABSTRACT
Objective: To study the chemical constituents of Artemisia integrifolia. Methods: Solvent extraction, silica gel column chromatography, and HPLC were used for isolation and purification. The structure was identified by NMR spectrum analysis. Anti-oxidant activity tests were performed using DPPH. Results: A total of 21 monomeric compounds were isolated from A. integrifolia and identified as 2R-(2Z-pentenoic acid methyl ester)-3S-(methyl acetate) cyclopentanone (1), methyl-4S-6α-hydroxy-3- oxoeudesma-1,11 (13)-dien-12-oate (2), methyl caffeate (3), dextrin inositol (4), monobutyl fumarate (5), caffeic acid (6), monobutyl malonate (7), 6,8-dimethoxycoumarin-7-O-β-D-glucoside (8), 3,5-O-di-caffeoyl quinic acid butyl ester (9), 3,4-O-dicaffeoyl quinic acid butyl ester (10), 4,5-O-dicaffeoyl quinic acid butyl ester (11), 3,5-O-dicaffeoyl quinic acid methyl ester (12), 4,5-O- dicaffeoylquinic acid (13), 1,5-O-dicaffeoylquinic acid (14) 3,5-O-dicaffeoylquinic acid (15), o-hydroxycinnamic acid glucoside (16), 1,3-O-dicaffeoyl quinic acid (17), chlorogenic acid (18), 3,4-O-dicaffeoylquinic acid (19), methyl 3,4-O-dicaffeoylquinate (20), and o-hydroxycinnamate methyl glucoside (21). Conclusion: Compound 1 is a new natural product. Compounds 2, 5, 7-11, 14, 16, and 21 are isolated from Artemisia for the first time, and the rest are isolated from A. integrifolia for the first time. Both caffeoyl quinic acid compounds had strong anti-oxidant capacity, and the activity is basically equivalent to Vc.
ABSTRACT
<p><b>Objective</b>To evaluate the efficacy and safety of intracytoplasmic morphologically selected sperm injection (IMSI) versus intracytoplasmic sperm injection (ICSI) in in vitro fertilization (IVF) for couples with male factor infertility.</p><p><b>METHODS</b>Using the Cochrane system evaluation method, we searched MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov, and SinoMed and manually searched the reference lists of the included studies and relevant reviews for randomized controlled trials (RCT) comparing ICSI and IMSI published from 1992 to July 2017. We performed a meta-analysis on the included literature with the RevMan 5.3 software and subgroup analyses due to the prominent clinical heterogeneity of the patients.</p><p><b>RESULTS</b>Of the 280 articles retrieved, 8 RCTs were included, involving 1 741 IVF cycles (842 cycles of IMSI versus 899 cycles of ICSI). There was no evidence for any significant difference between IMSI and ICSI in the live birth rate in the subgroup of infertility induced by pure male factors (RR = 1.31, 95% CI: 0.68－2.51; very low quality evidence from 1 RCT with 77 cycles) but an association of IMSI with an increased clinical pregnancy rate (RR = 1.46, 95% CI: 1.02－2.07; low quality evidence from 4 RCTs with 813 cycles), nor was there any evidence for that in the live birth rate (RR = 0.88, 95% CI: 0.60－1.31; low quality evidence from 1 RCT with 255 cycles) or clinical pregnancy rate (RR = 1.03, 95% CI: 0.86－1.23; moderate quality evidence from 3 RCTs with 851 cycles) in the subgroup of infertility caused by accompanying male factors.</p><p><b>CONCLUSIONS</b>The evidence is of low quality for the association of IMSI with an increased rate of clinical pregnancy and is not sufficient to support the routine use of IMSI in IVF for male factor infertility.</p>
Subject(s)
Female , Humans , Male , Pregnancy , Fertilization in Vitro , Methods , Infertility, Male , Therapeutics , Pregnancy Rate , Randomized Controlled Trials as Topic , Sperm Injections, IntracytoplasmicABSTRACT
Objective To investigate the expression of ubiquitin specific peptidase 7 (USP7) in the sperm of infertile man suffering asthenozoospermia or oligoasthenozoospermia, and to explore its role in the pathogenesis of male infertility. Methods The semen samples were obtained from 120 donors attending the Fertility Clinic, the Centre of Reproductive Medicine, the Second Affiliated Hospital, Chongqing Medical University. The sperm specimens were divided into normozoospermia group (n=57), asthenozoospermia group (n =37) or oligoasthenozoospermia group (n =26) after semen analysis according to 2010 WHO standards. The localization and expression of USP7 were examined using immunofluorescence and Western blotting analysis in the three groups. Then the correlation between USP7 expression and sperm parameterswas analyzed. Results USP7 mainly localized in the middle part and main part of thesperm tail; the USP expression was significantly lower in asthenozoospermia group(0. 86 ± 0. 53) and oligoasthenozoospermia group (0. 62 ± 0. 43) compared with normozoospermia group (1. 63 ± 0. 76, P<0. 01). And USP7 expression was found positively correlated with the ratio of sperm moving forward(r = 0. 431 2, P =0. 008 7), total motility rate(r=0. 443 8, P =0. 006 7), and sperm concentration(r = 0. 455 0, P =0. 005 3). Conclusion The lowered expression of USP7 is related to the reduction of human sperm motility and concentration, indicating that USP7 expressionmay serve as an indicator for sperm quality evaluation in infertile men.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the potential protective effect of the mitochondria-targeted antioxidant Mitoquinone (MitoQ) on post-thaw human sperm.</p><p><b>METHODS</b>Semen samples were collected from 60 normal fertile men, each divided into six parts of equal volume to be incubated at 37 °C in normal saline (G0, control) or in the extender with 2 nmol/L (G1), 20 nmol/L (G2), 200 nmol/L (G3), 2 µmol/L (G4), and 20 µmol/L of MitoQ (G5). After one hour of incubation, the samples were subjected to computer-assisted semen analysis (CASA) for sperm motility, flow cytometry for reactive oxygen species (ROS), thiobarbituric acid assay for the concentration of malondialdehyde (MDA), and MitoTracker fluorescent staining and flow cytometry for the sperm mitochondrial membrane potential (MMP). Then, the semen were cryopreserved with none (B0), 200 nmol/L (B1), and 2 µmol/L of MitoQ (B2), followed by detection of the changes in the ROS, MDA, and MMP of the post-thaw sperm.</p><p><b>RESULTS</b>The percentage of progressively motile sperm and total rate of sperm motility were significantly higher in G3 ([30.8 ± 10.2]% and [70.6 ± 9.0]%) and G4 ([32.7 ± 13.5]% and [70.3 ± 11.9]%) than in G0 ([17.6 ± 5.0]% and [54.9 ± 11.5]%) (P < 0.05). The level of ROS dropped markedly with the increased concentration of MitoQ, 86.5 ± 31.6 in G3, 93.6 ± 42.0 in G4, and 45.1 ± 15.0 in G5, as compared with 160.8 ± 39.7 in G0 (P < 0.05). The content of MDA was remarkably lower in G3 ([0.9 ± 0.5] µmol/mg) and G4 ([0.9 ± 0.5] µmol/mg) than in G0 ([1.9 ± 1.1] µmol/mg) (P < 0.05), but not in G5 ([1.7 ± 0.7] µmol/mg), which was even higher than in G3 and G4 (P < 0.05). The MMP showed a significant reduction in G5 (1156 ± 216) in comparison with G0 (1701 ± 251) (P < 0.05) but exhibited no remarkable difference between G0 and G1 (1810 ± 298), G2 (1995 ± 437), G3 (1950 ± 334), or G4 (1582 ± 314). The percentage of progressively motile sperm and total rate of sperm motility after freezing-thawing were significantly decreased as compared with those of the fresh semen (P < 0.01), but both were remarkably higher in B1 ([3.2 ± 2.3]% and [ 43.0 ± 9.5]%) than in B0 ([0.8 ± 0.6]% and [26.5 ± 11.4]%) (P < 0.05). The ROS level was significantly lower in B1 and B2 than in B0 (34.6 ± 12. 3 and 37.0 ± 10.5 vs 56.9 ± 14.3, P < 0.05), and so was the MDA content ([1.4 ± 0.5] and [1.4 ± 0.6] µmol/mg vs [2.6 ± 1.0] µmol/mg, P < 0.05), but the MMP was markedly higher in B1 and B2 than in B0 (1010.0 ± 130.5 and 880.6 ± 128.6 vs 721.1 ± 24.8, P < 0.05).</p><p><b>CONCLUSION</b>Addition of MitoQ to the freezing extender at 200 nmol/L may effectively improve the quality of human sperm and MitoQ is a good protective addictive for human sperm cryopreservation.</p>